EP3861987A4 - Combination medicine comprising drug-encapsulating liposome composition and platinum preparation - Google Patents
Combination medicine comprising drug-encapsulating liposome composition and platinum preparation Download PDFInfo
- Publication number
- EP3861987A4 EP3861987A4 EP19869479.6A EP19869479A EP3861987A4 EP 3861987 A4 EP3861987 A4 EP 3861987A4 EP 19869479 A EP19869479 A EP 19869479A EP 3861987 A4 EP3861987 A4 EP 3861987A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- drug
- liposome composition
- combination medicine
- platinum preparation
- encapsulating liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title 2
- 239000003814 drug Substances 0.000 title 1
- 239000002502 liposome Substances 0.000 title 1
- 229910052697 platinum Inorganic materials 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018186541 | 2018-10-01 | ||
PCT/JP2019/038708 WO2020071349A1 (en) | 2018-10-01 | 2019-10-01 | Combination medicine comprising drug-encapsulating liposome composition and platinum preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3861987A1 EP3861987A1 (en) | 2021-08-11 |
EP3861987A4 true EP3861987A4 (en) | 2021-09-15 |
Family
ID=70054620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19869479.6A Pending EP3861987A4 (en) | 2018-10-01 | 2019-10-01 | Combination medicine comprising drug-encapsulating liposome composition and platinum preparation |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210213051A1 (en) |
EP (1) | EP3861987A4 (en) |
JP (1) | JP7057434B2 (en) |
CN (1) | CN112789032A (en) |
WO (1) | WO2020071349A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116763734A (en) | 2017-03-31 | 2023-09-19 | 富士胶片株式会社 | Method for producing liposome composition |
TW202313031A (en) * | 2021-05-24 | 2023-04-01 | 日商富士軟片股份有限公司 | Anti-tumor agent |
EP4349338A1 (en) * | 2021-05-24 | 2024-04-10 | FUJIFILM Corporation | Treatment agent |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060008909A1 (en) * | 2004-05-17 | 2006-01-12 | Inex Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
US20090285878A1 (en) * | 2004-11-05 | 2009-11-19 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal drug formulations |
US20110159080A1 (en) * | 2008-06-03 | 2011-06-30 | Colin Lowery | Composition comprising liposome-entrapped doxorubicin and methods of administration |
WO2018083470A1 (en) * | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2566559A (en) * | 1951-09-04 | Preparation of agetals | ||
US2582242A (en) * | 1947-11-29 | 1952-01-15 | Johnson & Johnson | Cast for orthopedic use |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
EP1121102B1 (en) | 1998-09-16 | 2003-04-23 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
DE60115044T2 (en) | 2000-06-30 | 2006-08-03 | Inex Pharmaceuticals Corp., Burnaby | Liposomal antineoplastic drugs and their uses |
WO2012091054A1 (en) | 2010-12-27 | 2012-07-05 | テルモ株式会社 | Liposome composition and process for production thereof |
CN102764234A (en) * | 2012-08-03 | 2012-11-07 | 上海现代药物制剂工程研究中心有限公司 | Topotecan hydrochloride targeted liposome preparation and preparation method thereof |
EP3129062A4 (en) * | 2014-04-01 | 2017-11-29 | Children's Hospital Los Angeles | Targeted polymerized nanoparticles for cancer treatment |
KR102084340B1 (en) * | 2015-11-02 | 2020-03-03 | 후지필름 가부시키가이샤 | Tumor Therapeutics and Kits Including Gemcitabine Liposomal Composition |
CN116763734A (en) * | 2017-03-31 | 2023-09-19 | 富士胶片株式会社 | Method for producing liposome composition |
-
2019
- 2019-10-01 JP JP2020550444A patent/JP7057434B2/en active Active
- 2019-10-01 WO PCT/JP2019/038708 patent/WO2020071349A1/en unknown
- 2019-10-01 CN CN201980064960.5A patent/CN112789032A/en active Pending
- 2019-10-01 EP EP19869479.6A patent/EP3861987A4/en active Pending
-
2021
- 2021-03-31 US US17/219,064 patent/US20210213051A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
US20060008909A1 (en) * | 2004-05-17 | 2006-01-12 | Inex Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
US20090285878A1 (en) * | 2004-11-05 | 2009-11-19 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal drug formulations |
US20110159080A1 (en) * | 2008-06-03 | 2011-06-30 | Colin Lowery | Composition comprising liposome-entrapped doxorubicin and methods of administration |
WO2018083470A1 (en) * | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
Non-Patent Citations (3)
Title |
---|
JOHNSTON ET AL: "Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin", BBA - BIOMEMBRANES ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1768, no. 5, 11 April 2007 (2007-04-11), pages 1121 - 1127, XP022026692, ISSN: 0005-2736, DOI: 10.1016/J.BBAMEM.2007.01.019 * |
SADZUKA Y ET AL: "EFFECT OF POLYETHYLENEGLYCOL (PEG) CHAIN ON CELL UPTAKE OF PEG-MODIFIED LIPOSOMES", JOURNAL OF LIPOSOME RESEARCH, TAYLOR & FRANCIS, PHILADELPHIA, PA, US, vol. 13, no. 2, 1 January 2003 (2003-01-01), pages 157 - 172, XP001166721, ISSN: 0898-2104, DOI: 10.1081/LPR-120020318 * |
See also references of WO2020071349A1 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2020071349A1 (en) | 2021-09-02 |
TW202034912A (en) | 2020-10-01 |
EP3861987A1 (en) | 2021-08-11 |
US20210213051A1 (en) | 2021-07-15 |
CN112789032A (en) | 2021-05-11 |
JP7057434B2 (en) | 2022-04-19 |
WO2020071349A1 (en) | 2020-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3603620A4 (en) | Liposome composition and pharmaceutical composition | |
EP3732185A4 (en) | Conjugates and preparation and use thereof | |
EP3337456A4 (en) | Liposomes with ginsenoside as membrane material and preparations and use thereof | |
EP3658134A4 (en) | Liposome compositions comprising weak acid drugs and uses thereof | |
EP3706741A4 (en) | Pharmaceutical composition and use thereof | |
EP3825308A4 (en) | Compound, composition, and use thereof in preparation of drug | |
EP3434285A4 (en) | Pharmaceutical composition and use thereof | |
EP3861987A4 (en) | Combination medicine comprising drug-encapsulating liposome composition and platinum preparation | |
EP3721890A4 (en) | Ophthalmic drug preparation and uses thereof | |
EP3639845A4 (en) | Il-15 protein complex pharmaceutical composition and uses thereof | |
EP3851121A4 (en) | Human anti-il-33 monoclonal-antibody-containing pharmaceutical composition | |
EP3593785A4 (en) | Dental composition and preparation method therefor | |
EP3824897A4 (en) | Traditional chinese medicine composition and preparation method and application thereof | |
EP3492466A4 (en) | Oral solid preparation and use thereof | |
EP3773654A4 (en) | Polypharmaceutical drug compositions and related methods | |
EP3741748A4 (en) | Compound and use thereof in medicine | |
EP3878435A4 (en) | Irinotecan liposome preparation, and preparation and application thereof | |
EP3760191A4 (en) | Pharmaceutical composition and preparation method therefor and use thereof | |
ZA201905763B (en) | Liposomal compositions and solid oral dosage forms comprising the same | |
EP3777866A4 (en) | Pharmaceutical composition and application thereof | |
EP3999056A4 (en) | Pharmaceutical combination and use thereof | |
EP3957328A4 (en) | Lipid pharmaceutical preparation and application thereof | |
EP3880183A4 (en) | Pharmaceutical preparation of fruquintinib and use thereof | |
EP3915978A4 (en) | N-benzyl-n-arylsulfonamide derivative and preparation and use thereof | |
EP3813842A4 (en) | Pharmaceutical composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210330 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210817 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 43/00 20060101ALI20210811BHEP Ipc: A61P 35/00 20060101ALI20210811BHEP Ipc: A61K 47/28 20060101ALI20210811BHEP Ipc: A61K 47/24 20060101ALI20210811BHEP Ipc: A61K 47/04 20060101ALI20210811BHEP Ipc: A61K 33/243 20190101ALI20210811BHEP Ipc: A61K 31/704 20060101ALI20210811BHEP Ipc: A61K 31/4745 20060101ALI20210811BHEP Ipc: A61K 31/404 20060101ALI20210811BHEP Ipc: A61K 9/127 20060101AFI20210811BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |